nasal vaccine - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Representative image illustrating rising takeover speculation around Papa John’s International, Inc., as renewed private equity interest and a reported $65-per-share bid from TriArtisan Capital Advisors push the PZZA stock back into focus amid ongoing turnaround efforts.

Papa John’s agrees to explore sale as renewed private equity interest lifts PZZA

CyanVac’s nasal COVID-19 vaccine

Read More

5 minute read

Pharma Industry News

CyanVac’s nasal COVID-19 vaccine shows strong immune response in U.S. phase 1 clinical trial

CyanVac’s nasal COVID-19 vaccine shows strong mucosal immune response in U.S. phase 1 trial. Larger studies underway to assess full efficacy.

byPallavi Madhiraju

July 5, 2025

web analytics